Biotech Values

[mcbio]

I’m not clear on what you’re driving at—please clarify.

I'm just saying that ISIS is the one that seems to have let the cat out of the bag on PCSK9 and it obviously affects their PCSK9 drug. But, at the same time, ISIS' own mipomersen is much further ahead in the clinic and I believe there is some degree in overlap between mipo and the PCSK9 drugs in terms of target population. Removal of the threat of what was viewed as a blockbuster class in PCSK9 is presumably a positive for ISIS' own mipomersen.